Correction, 1 October 2026: The original article said Novo Nordisk could never be bought and ranked its Foundation as the world’s largest charity using volatile, non-comparable asset figures. The Foundation is obliged to maintain control, but those absolute and ranking claims were too strong.
Novo Nordisk is, depending on the week, the most valuable company in Europe or close to it — the maker of Ozempic and Wegovy, the drugs that turned appetite itself into a hundred-billion-dollar market.
Novo Nordisk is insulated from a conventional hostile takeover because the Novo Nordisk Foundation, through Novo Holdings, controls the voting majority and is obliged to maintain a controlling interest.
That makes a takeover unavailable without a fundamental change in the controlling owner’s position and governing arrangements; it is not a claim that corporate control can never change under any legal circumstances.
The charity that owns the company
The controlling owner of Novo Nordisk is the Novo Nordisk Foundation in Copenhagen, whose roots run back to the 1920s, when the Danish pioneers of insulin production placed their enterprises under foundation ownership; the modern foundation was consolidated from those original bodies.
The structure is a Danish specialty called an enterprise foundation — a self-owning institution with no shareholders and no members, existing only to carry out its charter. And the charter commits it to two jobs: maintain the commercial activities of the Novo companies, and give the resulting wealth away to science and society.
The Foundation reports that at the end of 2025 Novo Holdings held 28.1% of Novo Nordisk’s share capital and 77.3% of its votes. That voting structure blocks an ordinary hostile acquisition while the Foundation maintains control.
Then came Ozempic
For most of a century this was a Danish curiosity. Then the company the foundation is chained to invented the most commercially explosive medicines of the age.
The Foundation’s 2025 annual report records DKK 11.8 billion awarded for charitable purposes. Its parent-company accounts carry some investments at historical cost, while market-based rankings use other conventions, so cross-foundation asset comparisons are not straightforward.
The honest asterisks
The comparison with Gates needs its footnotes, and the foundation’s own leadership supplies them.
Comparisons with Gates, Wellcome and other foundations depend on valuation date, accounting perimeter and whether company-control holdings are counted at market or book value. The earlier article’s crown was therefore not a reliable fact.
And critics exist on both flanks: pricing campaigners note the fortune rests partly on decades of expensive insulin and now expensive weight-loss drugs, while philanthropy scholars worry about unelected mega-funders steering global health. A charity that owns a drug company sits, permanently, on both sides of several arguments.
What the arrangement actually buys
Strip the numbers away and the design is the interesting part.
Foundation control can support a long time horizon, but the sources cited here do not establish that it caused Novo Nordisk’s research strategy or that no stakeholder could influence the company.
The arrangement links long-term corporate control with a large grant-making institution. Its significance does not require an unverified claim that Denmark holds a global record.
How the structure works
The Foundation does not hold its listed-company stake directly for day-to-day trading. Novo Holdings manages the ownership and investment activities, while the Foundation’s objects and articles require it to preserve a controlling interest in Novo Nordisk and Novo Nordisk’s associated group. At the end of 2025, the reported 77.3% voting share gave it decisive control despite a much smaller economic share.
That makes an unsolicited takeover impractical under the present structure: buying publicly traded B shares would not deliver the voting majority. It is still important to describe this as governance, not a law of nature. Articles can be amended under their rules, legislation can change and corporate reorganisations are possible, even when none is currently proposed.
The Foundation’s charitable scale is best expressed through its own grants and accounts. In 2025 it awarded DKK 11.8 billion for charitable purposes. Comparing its total assets with other foundations can mislead because enterprise foundations consolidate or value company interests differently, share prices move, and some rankings mix endowment value with annual giving. The corrected article therefore reports the voting control and grant total without awarding a global crown.
The weight-loss-drug boom can affect the market value of the Foundation’s holding, but that does not mean a stock-price gain arrives as freely spendable cash. Grants depend on dividends, investment income, budgets and governance decisions. Distinguishing voting control, market value, accounting equity and annual giving prevents four different measures from being treated as one pile of money.
For readers, the durable fact is institutional control: a Danish enterprise foundation holds the voting power and directs substantial annual grants. The more dramatic superlatives depend on changing prices and incompatible accounting measures, so they have been removed.
